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Strongyloides stercoralis is an intestinal nematode endemic to tropical and sub-tropical regions. Although
infection is typically asymptomatic or self-limited, immunocompromised individuals can develop
a severe form of disease marked by hyperinfection. Pulmonary involvement accompanies hyperinfection
in a majority of cases, though manifestations range from asymptomatic inﬁltrates to diffuse alveolar
hemorrhage (DAH) and respiratory failure. When complicated by DAH, the hyperinfection syndrome is
usually fatal. We report a case of a 65-year-old Guatemalan woman with chronic inﬂammatory demy-
elinating polyneuropathy (CIDP) treated with chronic steroids who presented with Escherichia coli
urosepsis. She was initially treated with antibiotics and corticosteroids. She subsequently developed DAH
due to disseminated strongyloidiasis. She was treated with oral and subcutaneous ivermectin and had
complete recovery.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case report
A 65-year-old Guatemalan woman presented to the hospital
with two days of nausea, vomiting, and diarrhea. Her medical
history included CIDP, requiring 40e60 mg of prednisone daily.
Twenty years previously, she emigrated fromGuatemala but visited
her native country annually. Medications on admission included
prednisone 60 mg daily. She had a prior positive Strongyloides
serology (titer 2.11 index value) and peripheral eosinophilia (3400/
mm3) without documentation of prior anti-helminthic treatment.
On presentation, her vital signs were: blood pressure 94/
72 mmHg, heart rate 158 beats/min, respiratory rate 26 breaths/
min, oxygen saturation 94% on 2 L/min O2 via nasal cannula, and
temperature 37.0 C. Physical exam revealed rigors, dry mucous
membranes, clear lung ﬁelds, and suprapubic tenderness. Her WBCchronic inﬂammatory demy-
orrhage; ICU, intensive care
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-NC-ND license. count was 22,000/mm3 (19% bands and 0% eosinophils). Urinalysis
revealed 22 WBC/high powered ﬁeld. In the emergency depart-
ment, she received IV ﬂuids, ciproﬂoxacin, metronidazole, and
methylprednisolone 100 mg IV. She was admitted to the intensive
care unit (ICU) and started on piperacillin-tazobactam. Methyl-
prednisolone was discontinued and prednisone 30 mg twice daily
was begun. Admission blood and urine cultures grew Escherichia
coli. Stool studies were negative for enteric pathogens. On hospital
day 2, her hemodynamic status improved and she was transferred
to the medical ward.
On hospital day 5, she developed progressive hypoxemia.
Contrast-enhanced chest CT identiﬁed small bilateral pleural effu-
sions and diffuse perihilar and peripheral air space opacities. Chest
X-ray on hospital day 8 demonstrated progressive bilateral inﬁl-
trates (Fig. 1). Bronchoscopy demonstrated blood throughout the
tracheobronchial tree. Serial aliquots of bronchoalveolar lavage
(BAL) ﬂuid revealed persistently hemorrhagic ﬂuid. She was intu-
bated and transferred to the ICU. Repeat WBC count was 24,000/
mm3 (7% bands and 13% eosinophils), platelets 348,000/mm3, and
prothrombin time 13.9 s. Given bronchoscopic evidence of DAH,
she was treated with 1 g of methylprednisolone daily for two days.
Prior to methylprednisolone, she received a dose of oral ivermectin
(200 mcg/kg). The following day, BAL ﬂuid returned positive for
Strongyloides stercoralis (Fig. 2). Corticosteroids were discontinued.
Fig. 1. AP chest X-ray demonstrating diffuse patchy opaciﬁcation.
Fig. 2. Strongyloides ﬁlariform larva from BAL, 100 magniﬁcation.
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day for 4 doses. Repeat bronchoscopy on hospital day 9 showed
resolving hemorrhage. Serologies were negative for ANCA,
anti-GBM, ANA, HIV, and HTLV-1. Stool studies were monitored to
document Strongyloides clearance. Our patient improved over the
next 10 days and was discharged in good condition to complete
a total of 4 weeks of daily oral ivermectin therapy.
2. Discussion
S. stercoralis, an intestinal nematode endemic to Africa, South-
east Asia, Central and South America, has a complex life cycle
involving the pulmonary and gastrointestinal systems.1 Infection is
often asymptomatic. Symptomatic disease ranges from nonspeciﬁc
cutaneous, gastrointestinal, and respiratory manifestations to an
often fatal hyperinfection syndrome. Pulmonary symptoms include
cough, dyspnea, wheezing, and hemoptysis. An asthma-like
syndrome can be seen with chronic Strongyloides infection. Respi-
ratory symptoms are thought to be caused by larval migrationacross alveolar-septal walls, larval maturation in pulmonary
parenchyma, or widespread dissemination during the hyper-
infection syndrome.2
A hyperinfection syndrome occurs when decreased cell-
mediated immunity enables accelerated autoinfection, causing
widespread parasitemia. Risk factors for hyperinfection include
corticosteroids, stem-cell transplantation, alcoholism, HIV, and
HTLV-1 infection. Common manifestations include fever, abdom-
inal pain, anemia, and diarrhea.3,4 Gram-negative bacteremia is
a frequent complication, resulting from bacterial translocation in
the intestine due to mucosal disruption by Strongyloides larvae.
Pulmonary symptoms develop in 85% of hyperinfection
patients.2 Manifestations include pulmonary inﬁltrates, DAH, and
respiratory failure, all of which developed in our patient. Though
she also had E. coli bacteremia, we believe this was due to urosepsis
rather than intestinal translocation.
S. stercoralis hyperinfection carries a high mortality rate of
70e89% in modern series.1,3,4 All cases complicated by DAH in the
medical literature have reported fatal outcomes. Detection of
disseminated disease requires high clinical suspicion. Diagnosis is
often made by identiﬁcation of larvae in stool, sputum, or BAL ﬂuid.
Ivermectin or albendazole are ﬁrst-line treatments for uncompli-
cated infection. In disseminated disease, optimal treatment
remains uncertain. Oral ivermectin may be ineffective due to ileus
associated with hyperinfection syndrome. Thus, subcutaneous
ivermectin has been used in cases of disseminated Strongyloides.5
It is unclear why our patient developed the hyperinfection
syndrome during this admission since she had been on cortico-
steroids for the preceding 3 months. It is possible that the admin-
istration of IV methylprednisolone on admission resulted in further
immunosuppression and precipitated her deterioration. Our
patient improved dramatically after treatment with oral and
subcutaneous ivermectin. She represents the ﬁrst case of survival in
DAH from disseminated Strongyloides. In spite of this success, the
ideal treatment for disseminated strongyloidiasis remains
unknown.
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